• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:田圆圆,张群英.重组人干扰素α2β治疗后HR HPV DNA负荷量、HPV16-E7蛋白和VEGF_C表达水平对宫颈鳞癌的预测价值研究[J].中国现代应用药学,2018,35(6):891-894.
TIAN Yuanyuan,ZHANG Qunying.Predictive Value Study of HR HPV DNA Load, HPV16-E7 Protein and VEGF_C Expression After Recombinant Human Interferon α2β on Squamous Cell Carcinoma of the Cervix Cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2018,35(6):891-894.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2337次   下载 1760 本文二维码信息
码上扫一扫!
分享到: 微信 更多
重组人干扰素α2β治疗后HR HPV DNA负荷量、HPV16-E7蛋白和VEGF_C表达水平对宫颈鳞癌的预测价值研究
田圆圆, 张群英
长兴县妇幼保健院妇产科, 浙江 长兴 313100
摘要:
目的 研究重组人干扰素α2β治疗后高危(high risk,HR) HPV DNA负荷量、HPV16-E7蛋白和VEGF_C表达水平变化及其对宫颈鳞癌的预测价值。方法 选取35例慢性宫颈炎、25例宫颈鳞癌前病变以及30例宫颈鳞癌患者作为研究对象,患者均接受重组人干扰素α2β治疗。分别于治疗前后,应用第2代杂交捕获法测定HR HPV DNA负荷量,应用SP免疫组化法测定HPV16-E7蛋白和VEGF_C表达水平。应用SPSS软件分析HR HPV DNA负荷量、HPV16-E7蛋白和VEGF_C对于宫颈鳞癌的预测价值。结果 治疗后,宫颈鳞癌组HR HPV DNA负荷量显著高于癌前病变组(P<0.05),癌前病变组显著高于慢性宫颈炎组(P<0.05)。与治疗前比较,各组的HPV16-E7蛋白和VEGF_C表达水平未显著降低,宫颈鳞癌前病变组显著高于慢性宫颈炎组(P<0.05),宫颈鳞癌组显著高于宫颈鳞癌前病变组(P<0.05)。多元逐步logistic回归分析显示:宫颈鳞癌=-2.763+0.275 HR HPV DNA负荷量+1.581 HPV16-E7蛋白+1.216 VEGF_C(c2=36.781,P<0.001),经hosmer-leme-show检验显示,观测数据与预测数据无显著性差异。ROC曲线显示,HR HPV DNA负荷量、HPV16-E7蛋白和VEGF_C联合用于宫颈鳞癌的预测的AUC最大(0.91)。结论 重组人干扰素α2β治疗后,HR HPV DNA负荷量联合HPV16-E7蛋白和VEGF_C对宫颈鳞癌的预测效果较好。
关键词:  重组人干扰素α2β  HR HPV DNA负荷量  HPV16-E7蛋白  VEGF_C
DOI:10.13748/j.cnki.issn1007-7693.2018.06.023
分类号:R969.3
基金项目:湖州市科研计划项目(2015GY54)
Predictive Value Study of HR HPV DNA Load, HPV16-E7 Protein and VEGF_C Expression After Recombinant Human Interferon α2β on Squamous Cell Carcinoma of the Cervix Cancer
TIAN Yuanyuan, ZHANG Qunying
Obstetrics and Gynecology Department of Changxin maternal and child health care hospital, Changxing 313100, China
Abstract:
OBJECTIVE To investigate the changes of high risk (HR) HPV DNA load, HPV16-E7 protein and VEGF_C expression and their predictive value in cervical squamous cell carcinoma after recombinant human interferon α2β treatment. METHODS The 35 cases of chronic cervicitis, 25 cases of cervical precancerous lesions and 30 cases of cervical cancer were selected as study subjects. Patients were treated with recombinant human interferon α2β. The expression levels of HPV16-E7 protein and VEGF_C were detected by SP immunohistochemistry before and after treatment while the second generation hybridization capture method was used to dectect HR HPV DNA load. The application of SPSS software analysis of HR HPV DNA load, HPV16-E7 protein and VEGF_C for cervical squamous cell carcinoma predictive value. RESULTS After treatment, the HPV-DNA load in cervical cancer group was significantly higher than that in precancerous lesions group (P<0.05), and it was significantly higher in precancerous lesions group than that in chronic cervicitis group (P<0.05). Compared with before treatment, the expression of HPV16-E7 protein and VEGF_C were not significantly decreased, but were significantly higher in cervical precancerous lesions than those in chronic cervicitis (P<0.05). Cervical squamous cell carcinoma was significantly higher than that in precancerous lesions (P<0.05). Multivariate stepwise logistic regression analysis showed that cervical cancer=-2.763+0.275 HR HPV DNA load+1.581 HPV16-E7 protein+1.216 VEGF_C (c2=36.781, P<0.001). The results of hosmer-leme-show showed that there was no significant different between observation data and forecast data. The ROC curve showed the highest AUC (0.91) for HR HPV DNA load, HPV16-E7 protein and VEGF_C combined for predicting cervical squamous cell carcinoma. CONCLUSION The effect of HR HPV DNA load combined with HPV16-E7 protein and VEGF_C on cervical squamous cell carcinoma is great after recombinant human interferon α2β treatment.
Key words:  recombinant human interferon α2β  HR HPV DNA load  HPV16-E7 protein  VEGF_C
扫一扫关注本刊微信